Ajay Nooka, MD, MPH
Enriched profileProfessor, Department of Hematology and Medical Oncology, Emory University School of Medicine; Director, Myeloma Program; Associate Director of Clinical Research, Winship Cancer Institute · Winship Cancer Institute of Emory University
Ajay Nooka is Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine; Director, Myeloma Program; Associate Director of Clinical Research, Winship Cancer Institute at Winship Cancer Institute of Emory University. OpenAlex indexes 691 publications with 15,796 citations (h-index 55); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Ajay Nooka, MD, MPH,FACP, is Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine at Winship Cancer Institute of Emory University. The public record shows 691 publications with 15,796 citations (h-index 55), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 17 companies.
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Multiple Myeloma Research and Treatments
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 46 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 172.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Temporary voting member
FDA Oncologic Drugs Advisory Committee (ODAC), participated in April 2024 MRD-endpoint discussion for multiple myeloma trials and the May 20-21, 2025 ODAC meeting
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fda.gov ↗ - Participant
FDA-AACR Workshop (Feb 13, 2020) on under-representation of African Americans in Multiple Myeloma Clinical Trials
2020provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Sponsor: Emory University
Industry payments
Updated 14 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202520 payments$12,045openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20255 payments
- GlaxoSmithKline, LLC.Program year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.4%Thalidomide Analog34.1%Lenalidomide36%Pomalyst36%Revlimid28%Part D≥33 patientsProteasome Inhibitor7.6%Ninlaro100%Part D≥12 patients+ 3 more classes in this area
Anti-infectives
15.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12%Valacyclovir100%Part D≥51 patientsHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor1.9%Entecavir100%Part D<11 patients+ 1 more class in this area
Nervous system
11%Opioid Agonist9.2%Oxycodone Hcl100%Part D≥41 patientsGabapentinoids1.8%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
180 congress contributions (2006–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety.
ASCO Annual Meeting
ASCO2026Co-author - Using artificial intelligence (AI) as a decision support tool in clinic.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
American journal of hematology
Article2026 - Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Review2026 - Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.
Clinical cancer research
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma1,515 citations2016
- 02Teclistamab in Relapsed or Refractory Multiple Myeloma1,130 citations2022
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ajay-nooka-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/ajay-nooka-209a8aa1
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Ajay-Nooka
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/AjayNookaMD
Mentions by others
where others cite or feature them- Instagram
instagram.com/winshipatemory/p/CwlAFlAtD74
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
winshipcancer.emory.edu/newsroom/articles/2023/nooka-named-associate-director-for-clinical-research-at-winship.php
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →winshipcancer.emory.edu ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - Onclive.com
OncLive author profile, regularly featured in video interviews and authored clinical commentary on multiple myeloma therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Doximity
Doximity provider profile
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
Editorial & leadership roles
journal and society appointments- Director
Myeloma Program, Department of Hematology and Medical Oncology, Emory University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Associate Director of Clinical Research
Winship Cancer Institute of Emory University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Scientific Director
Winship Data and Technology Applications Shared Resource
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Steering committee member
Multiple Myeloma Research Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- ASCO Merit Award2011verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
Cancer Prevention and Control Research Program, Winship Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Attending physician
Emory University Hospital Midtown / Winship Cancer Institute at Emory Midtown, 36 Linden Ave NE, Atlanta, GA 30308
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- Myeloma Crowd Radio interview (YouTube)
smoldering-to-active myeloma progression
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - OncLive video/authored-content series
bispecific antibodies, teclistamab, elranatamab in multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - AJMC video interview series
MRD testing and MajesTEC-3 trial in multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗ - Blood Cancers Today
commentary on FDA accelerated approval of elranatamab
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Suresh Ramalingam, MBBS
Winship Cancer Institute of Emory University
Sagar Lonial, MD
Winship Cancer Institute of Emory University
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens